Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950334 · ClinicalTrials.gov registry record · Phase 1
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05950334 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT05950334, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Bendamustine
- DRUG FT522
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950334
The ClinicalTrials.gov registry entry for NCT05950334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05950334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05950334 about?
NCT05950334 is a clinical study titled "FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)". This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D...
What is the current status of trial NCT05950334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-11-16. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05950334?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), Bendamustine (DRUG), FT522 (DRUG).
Who is sponsoring clinical trial NCT05950334?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.